AgomAb Therapeutics (NASDAQ:AGMB) Director Purchases $103,500.00 in Stock

AgomAb Therapeutics NV (NASDAQ:AGMB) Director David Epstein purchased 15,000 shares of the company’s stock in a transaction that occurred on Thursday, November 5th. The shares were acquired at an average cost of $6.90 per share, with a total value of $103,500.00. Following the completion of the acquisition, the director directly owned 40,000 shares in the company, valued at approximately $276,000. This represents a 60.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

AgomAb Therapeutics Stock Performance

Shares of AGMB opened at $7.64 on Monday. The stock has a fifty day moving average price of $10.26 and a two-hundred day moving average price of $11.86. AgomAb Therapeutics NV has a 52-week low of $6.46 and a 52-week high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB) last announced its earnings results on Thursday, August 6th. The company reported ($0.46) EPS for the quarter. Analysts expect that AgomAb Therapeutics NV will post -1.77 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages recently issued reports on AGMB. Johnson Rice reiterated a “buy” rating on shares of AgomAb Therapeutics in a research report on Wednesday, October 21st. Cantor Fitzgerald assumed coverage on shares of AgomAb Therapeutics in a research report on Wednesday, August 19th. They issued an “overweight” rating for the company. HC Wainwright reaffirmed a “buy” rating on shares of AgomAb Therapeutics in a research note on Wednesday, October 21st. Wall Street Zen lowered shares of AgomAb Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, September 27th. Finally, Piper Sandler started coverage on shares of AgomAb Therapeutics in a research note on Tuesday, August 25th. They set an “overweight” rating and a $60.00 price target on the stock. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $37.50.

AgomAb Therapeutics Company Profile

Agomab Therapeutics N.V. is a clinical-stage biotechnology company focused on developing medicines that promote tissue regeneration and address diseases associated with fibrosis and tissue damage. The company’s research is centered on biological pathways involved in repair, remodeling and the disease microenvironment.

Agomab’s lead program is AGMB-129, an orally administered, gut-restricted small-molecule inhibitor of transforming growth factor beta receptor 1, also known as ALK5. The program is being developed for intestinal fibrosis associated with Crohn’s disease, a condition in which scar tissue can narrow the intestine and contribute to complications.

The company also maintains earlier-stage discovery and development programs intended to apply its regenerative medicine expertise to additional gastrointestinal and oncology-related indications.